The comparison of different daidzein-PLGA nanoparticles in increasing its oral bioavailability

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 559-570

  Ma, Yiran ^a   Zhao, Xinyi ^a   Li, Jian ^a   Shen, Qi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cyclodextrin inclusion complexes; Daidzein; Nanoparticles; Phospholipid complexes; PLGA

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; DAIDZEIN; PHOSPHOLIPID; POLYGLACTIN; ISOFLAVONE DERIVATIVE; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; CYCLODEXTRIN;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL STRUCTURE; COMPARATIVE STUDY; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MALE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SCANNING ELECTRON MICROSCOPY; STEREOLOGY; SUSPENSION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMICAL PHENOMENA; CHEMISTRY; ORAL DRUG ADMINISTRATION; SOLUBILITY; SPRAGUE DAWLEY RAT; TEMPERATURE; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG HALF LIFE; PLASMA CONCENTRATION-TIME CURVE; TIME TO MAXIMUM PLASMA CONCENTRATION;

RATTUS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; ISOFLAVONES; LACTIC ACID; MALE; NANOPARTICLES; PARTICLE SIZE; PHOSPHOLIPIDS; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TEMPERATURE;

EID: 84863014536     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Gutierrez RM, Baez EG. Cardioactive agents from plants. Mini Rev Med Chem. 2009;9(7):878-899.
2. Lo FH, Mak NK, Leung KN. Studies on the anti-tumor activities of the soy isofavone daidzein on murine neuroblastoma cells. Biomed Pharmacother. 2007;61(9):591-595.
3. Moller FJ, Diel P, Zierau O, Hertrampf T, Maass J, Vollmer G. Long-term dietary isofavone exposure enhances estrogen sensitivity of rat uterine responsiveness mediated through estrogen receptor alpha. Toxicol Lett. 2010;196(3):142-153.
4. Allred CD, Twaddle NC, Allred K F, et al. Soy processing affects metabolism and disposition of dietary isofavones in ovariectomized BALB/c mice. J Agric Food Chem. 2005;53(22):8542-8550.
5. Janning P, Schuhmacher US, Upmeier A, et al. Toxicokinetics of the phytoestrogen daidzein in female DA/Han rats. Arch Toxicol. 2000;74(8):421-430.
6. Qiu F, Chen XY, Song B, Zhong F, Liu CX. Infuence of dosage forms on pharmacokinetics of daidzein and its main metabolite daidzein-7-O-glucuronide in rats. Acta Pharmacol Sin. 2005;26(9):1145-1152.
7. Zheng Y, Lee SO, Verbruggen MA, Murphy PA, Hendrich S. The apparent absorptions of isofavone glucosides and aglucons are similar in women and are increased by rapid gut transit time and low fecal isofavone degradation. J Nutr. 2004;134(10):2534-2539.
8. Li X, Shen Q, Yuan D, Ma A, Jia W. Determination of daidzein in rat plasma by LC. Chromatographia. 2008;68(3-4):201-205.
9. Kulling SE, Honig DM, Metzler M. Oxidative metabolism of the soy isofavones daidzein and genistein in humans in vitro and in vivo. J Agric Food Chem. 2001;49(6):3024-3033.
10. Shen Q, Li X, Yuan D, Jia W. Enhanced oral bioavailability of daidzein by self-microemulsifying drug delivery system. Chem Pharm Bull (Tokyo). 2010;58(5):639-643.
11. Zhang Z, Huang Y, Gao F, Bu H, Gua W, Li Y. Daidzein-phospholipid complex loaded lipid nanocarriers improved oral absorption: in vitro characteristics and in vivo behavior in rats. Nanoscale. 2011;3(4):1780-1787.
12. Zhang Z, Huang Y, Gao F, et al. A self-assembled nanodelivery system enhances the oral bioavailability of daidzein: in vitro characteristics and in vivo performance. Nanomedicine (Lond). 2011;6(8):1365-1379.
13. Gao Y, Gu W, Chen L, Xu Z, Li Y. The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. Biomaterials. 2008;29(30):4129-4136.
14. Lavelle EC, Sharif S, Thomas N W, Holland J, Davis SS. The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv Drug Deliv Rev. 1995;18(1):5-22.
15. Agüeros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release. 2010;145(1):2-8.
16. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21(23):2475-2490.
17. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3): 329-347.
18. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1): 5-24.
19. Damge C, Aprahamian M, Marchais H, Benoit J P, Pinget M. Intestinal absorption of PLAGA microspheres in the rat. J Anat. 1996;189(Pt 3): 491-501.
20. Tewes F, Munnier E, Antoon B, et al. Comparative study of dox-orubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm. 2007;66(3):488-492.
21. Cui F, Shi K, Zhang L, Tao A, Kawashima Y. Biodegradable nano-particles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release. 2006;114(2):242-250.
22. Cirpanli Y, Bilensoy E, Lale Dogan A, Çalis S. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur J Pharm Biopharm. 2009;73(1): 82-89.
23. Jeffery H, Davis SS, O'Hagan DT. The preparation and characterisation of poly(lactide-co-glycolide) microparticles. I: oil-in-water emulsion solvent evaporation. Int J Pharm. 1991;77(2-3): 169-175.
24. Mu L, Feng SS. A novel controlled release formulation for the antican-cer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 2003;86(1):33-48.
25. Fessi H, Puisieux F, Devissaguet J P, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55:R1-R4.
26. Molpeceres J, Guzman M, Aberturas MR, Chacon M, Berges L. Application of central composite designs to the preparation of poly-caprolactone nanoparticles by solvent displacement. J Pharm Sci. 1996;85(2):206-213.
27. Aditya N P, Patankar S, Madhusudhan B, Murthy RS, Souto EB. Arthemeter-loaded lipid nanoparticles produced by modifed thin-flm hydration: pharmacokinetics, toxicological and in vivo anti-malarial activity. Eur J Pharm Sci. 2010;40(5):448-455.
28. Aquilano D, Cavalli R, Gasco MR. Solid lipospheres obtained from hot microemulsions in the presence of different concentrations of cosurfactant: the crystallization of stearic acid polymorphs. Thermochim Acta. 1993;230:29-37.
29. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowasky U, Ravi Kumar MN. Design of estradiol loaded PLGA nanopaticles formulations: a potential oral delivery system for hormone therapy. Pharm Res. 2006;23(1):184-195.
30. Arshady R. Preparation of biodegradable microspheres and microcapsules: 2. Polylactides and related polyesters. J Control Release. 1991;17(1):1-22.
31. Li X, Deng X, Yuan M, et al. Investigation on process parameters involved in preparation of poly-DL-lactide-poly(ethylene glycol) microspheres containing Leptospira Interrogans antigens. Int J Pharm. 1999;178(2):245-255.
32. Zhu KJ, Jiang HL, Du XY, Wang J, Xu WX, Liu S F. Preparation and characterization of hCG-loaded polylactide or poly(lactide-co-glycolide) microspheres using a modifed water-in-oil-in-water (w/o/w) emulsion solvent evaporation technique. J Microencapsul. 2001;18(2):247-260.
33. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly(D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release. 2002;82(1):105-114.
34. Ahlin P, Kristl J, Kristl A, Vrecer F. Investigation of polymeric nano-particles as carriers of enalaprilat for oral administration. Int J Pharm. 2002;239(1-2):113-120.
35. Yin Y, Chen D, Qiao M, Wei X, Hu H. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J Control Release. 2007;123(1):27-38.
36. Hasan AS, Socha M, Lamprecht A, et al. Effect of the microencapsu-lation of nanoparticles on the reduction of burst release. Int J Pharm. 2007;344(1-2):53-61.
37. Hurteaux R, Edwards-Levy F, Laurent-Maquin D, Levy MC. Coating alginate microspheres with a serum albumin-alginate membrane: application to the encapsulation of a peptide. Eur J Pharm Sci. 2005;24(2-3):187-197.
38. Ratzinger G, Fillafer C, Kerleta V, Wirth M, Gabor F. The role of surface functionalization in the design of PLGA micro- and nanoparticies. Crit Rev Ther Drug Carrier Syst. 2010;27(1):1-83.
39. Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev. 1998;34(2-3):221-233.
40. McClean S, Prosser E, Meehan E, et al. Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. Eur J Pharm Sci. 1998;6(2):153-163.
41. Dong Y, Feng SS. Poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(30):6068-6076.
42. O'Hagan DT, Jeffery H, Roberts MJ, McGee J P, Davis SS. Controlled release microparticles for vaccine development. Vaccine. 1991;9(10): 768-771.
43. Hancock BC, Carlson GT, Ladipo DD, Langdon BA, Mullarney M P. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int J Pharm. 2002;241(1): 73-85.
44. Corrigan DO, Healy AM, Corrigan OI. The effect of spray drying solutions of bendroflumethiazide/polyethylene glycol on the physicochemical properties of the resultant materials. Int J Pharm. 2003;262(1-2):125-137.
45. Foti P, Erba D, Spadafranca A, Ciappellano S, Bresciani J, Testolin G. Daidzein is absorbed by passive transport in isolated small intestine of rats. Nutr Res. 2006;26(6):284-288.
46. Fricker G, Kromp T, Wendel A, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res. 2010;27(8): 1469-1486.
47. Leigh M, van Hoogevest P, Tiemessen H. Optimising the oral bioavail-ability of the poorly water-soluble drug cyclosporin A using membrane lipid technology. Drug Deliv Syst. 2001;1(3):73-77.
48. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231-248.
49. Hamada H, Ishihara K, Masuoka N, Mikuni K, Nakajima N. Enhancement of water-solubility and bioactivity of paclitaxel using modifed cyclodextrins. J Biosci Bioeng. 2006;102(4):369-371.
50. Mady FM, Abou-Taleb AE, Khaled KA, et al. Evaluation of carboxym-ethyl-beta-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine. Int J Pharm. 2010;397(1-2):1-8.
51. Maiti K, Mukherjee K, Gantait A, Saha B P, Mukherjee PK. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007;330(1-2): 155-163.
52. Sachs-Barrable K, Lee SD, Wasan EK, Thornton SJ, Wasan KM. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. Adv Drug Deliv Rev. 2008;60(6):692-701.
53. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(15):2713-2722.
54. Florence AT, Hillery AM, Husain N, Jani PU. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release. 1995;36(1-2):39-46.